Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →In a retrospective cohort of 50 children and young adults with newly diagnosed ALL, treatment with a modified BFM-2009 protocol at an Indian government hospital produced 94% induction remission, 75.2% three-year event-free survival, and 78.3% three-year overall survival, with seven relapses and three treatment-related deaths.
The record provides evidence that a modified, risk-adapted BFM-2009 regimen can be delivered in a resource-constrained government hospital with substantial remission and survival rates; it remains an inference—not established by this uncontrolled retrospective study—that broader protocol adaptation and supportive-care optimization would improve outcomes in similar settings.
In a retrospective matched case-control study at one pediatric cancer center, children who ever reported high distress had greater odds of pediatric palliative care referral, while caregiver distress scores were not associated with referral.
The study provides associative evidence that high patient-reported distress can identify children more likely to receive palliative care referral; it remains an untested inference that prospectively using distress as a referral trigger would improve referral timing, symptoms, quality of life, or caregiver outcomes.
This article summarizes the potential of TNF-α inhibitors, particularly adalimumab, to control ocular inflammation, reduce glucocorticoid exposure, and improve visual outcomes in juvenile idiopathic arthritis-associated uveitis while highlighting unresolved dosing, tapering, discontinuation, and long-term safety questions.
The supplied record indicates that TNF-α inhibition may benefit children with inadequately controlled JIA-associated uveitis; it is reasonable but not demonstrated here to hypothesize that individualized initiation and dose-adjustment strategies could improve disease control and limit glucocorticoid toxicity.
In patients aged 1–21 years with newly diagnosed ALL on DFCI 16-001, pegaspargase rechallenge after a Grade 2 hypersensitivity reaction, with premedication and serum asparaginase activity monitoring, was successful in 41.3% of those rechallenged.
The record provides evidence that monitored pegaspargase rechallenge can preserve effective drug exposure without another reaction in a subset of patients; it remains an inference, not established practice, that this strategy could improve continuity of intended therapy or outcomes while reducing reliance on alternative asparaginase formulations.
This multicenter retrospective analysis identified TLS::ERG fusion in 12 of 875 children with AML and found frequent relapse and poor long-term survival despite an 83% complete remission rate after two induction courses.
The evidence supports TLS::ERG as a potential marker of a rare, relapse-prone pediatric AML subgroup; it may justify prospective evaluation for intensified surveillance, risk-adapted therapy, or alternative post-remission strategies, but the record does not demonstrate that any specific intervention improves outcomes.
This scoping review of 18 studies identifies patient attitudes, social and professional influences, financial and time constraints, health status, psychological factors, and access to decision support as contributors to fertility-preservation decisional conflict among reproductive-age women with cancer.
The review supports an association between modifiable decision-support factors and fertility-preservation decisional conflict; it is reasonable but unproven to infer that tailored counseling, decision aids, and earlier oncofertility referral could reduce conflict and improve fertility-preservation decision-making, including potentially for adolescent and young-adult patients.
In a single-institution retrospective review of 76 pediatric patients with relapsed or refractory malignancies, palliative single-agent oral etoposide was associated with stable disease in some imaged patients and fewer clinic visits, hospitalizations, and hospital days than the patients’ most recent prior treatment.
The supplied evidence indicates that oral etoposide can coincide with temporary disease stability and reduced treatment burden in this palliative setting; it supports, but does not establish, the hypothesis that oral etoposide may offer a comparatively low-burden disease-control option for selected children with relapsed or refractory malignancies.
In 1,581 adult male childhood cancer survivors, many—including most survivors with treatment-related risk factors—did not perceive themselves to be at increased risk for sexual dysfunction, indicating a substantial survivorship knowledge gap.
The study provides observational evidence that perceived sexual dysfunction risk is often discordant with treatment history; it is reasonable but unproven to hypothesize that individualized education and counseling could improve risk awareness, facilitate appropriate assessment, and potentially support earlier management of sexual health problems.
In a retrospective cohort of 21 pediatric patients with non-lymphoma solid tumors, combined whole-body MRI and 18F-FDG-PET/CT detected confirmed nodal and distant metastases with higher sensitivity than either modality alone while retaining high specificity.
The reported evidence suggests that combining WB-MRI with 18F-FDG-PET/CT may reduce missed metastases during staging; it is an inference—not tested here—that more accurate staging could improve treatment selection or that an MRI-led strategy could eventually reduce radiation exposure without compromising detection.
In a retrospective cohort of 1,200 women with germline pathogenic breast-cancer susceptibility variants, breastfeeding and diagnosis at least 10 years after the last childbirth were independently associated with better overall survival after invasive breast cancer.
The evidence supports reproductive timing and breastfeeding history as potential prognostic variables in hereditary breast cancer; it only suggests, rather than demonstrates, that incorporating these variables into risk stratification or surveillance could improve care, and it does not establish breastfeeding or any postpartum intervention as a treatment.
In a prospective observational study of 100 adults starting chemotherapy and/or radiotherapy, six weeks of prophylactic oral Lactobacillus supplementation was associated with less grade ≥2 diarrhea, lower mean diarrhea severity, reduced loperamide use, and a small improvement in physical functioning compared with standard care alone.
The record supports an association between prophylactic Lactobacillus and reduced treatment-associated diarrhea in adults; it remains an inference, requiring controlled trials, that probiotics causally prevent gastrointestinal toxicity or would provide similar benefit and safety in pediatric oncology patients.
In a matched observational cohort with mean follow-up of 15.6 years, children receiving TBI-based HSCT for ALL at ages 2 to <4 years did not have a greater overall long-term complication burden, poorer educational outcomes, or worse quality of life than older prepubertal children.
The reported human observational evidence suggests that age 2 to <4 years may not independently confer greater long-term toxicity after TBI-based HSCT; it can therefore motivate prospective validation of whether selected younger children could receive TBI-based conditioning, but it does not establish safety, comparative efficacy, or an optimal lower age threshold.
